Sunshine Biopharma (SBFM) Cash from Investing Activities (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Cash from Investing Activities came in at -$104518.0 in Q1 2026, up 50.7% YoY from -$69353.6 in Q1 2025, and down 108.17% on a QoQ basis from -$50209.0 in Q4 2025.
Sunshine Biopharma (SBFM) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 11 years of Cash from Investing Activities data on file, last reported at -$104518.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 50.7% year-over-year to -$104518.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$728807.0 (up 52.13% YoY) and the FY2025 annual result came in at -$836306.0, up 57.75% from the prior year.
- Cash from Investing Activities fell to -$104518.0 in Q1 2026, from -$50209.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $18859.0 in Q3 2023 to a low of -$14.6 million in Q4 2022.
- A 5-year average of -$1.3 million and a median of -$235746.5 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 98.16% — and 2024, when it slumped 3655.86%.
- Tracing SBFM's Cash from Investing Activities over 5 years: stood at -$14.6 million in 2022, then jumped by 98.16% to -$269230.0 in 2023, then jumped by 63.69% to -$97770.0 in 2024, then surged by 48.65% to -$50209.0 in 2025, then slumped by 108.17% to -$104518.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$104518.0 (Q1 2026), -$50209.0 (Q4 2025), and -$118295.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn | -5,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5,120.00 |
| Jun 30, 2026 | -5,120.00 |
| Mar 31, 2026 | -104,518.00 |
| Mar 31, 2026 | -104,518.00 |
| Dec 31, 2025 | -50,209.00 |
| Dec 31, 2025 | -50,209.00 |
| Sep 30, 2025 | -118,295.00 |
| Sep 30, 2025 | -118,295.00 |
| Jun 30, 2025 | -455,785.00 |
| Jun 30, 2025 | -455,785.00 |
| Mar 31, 2025 | -212,017.00 |
| Mar 31, 2025 | -212,017.00 |
| Dec 31, 2024 | -97,770.00 |
| Dec 31, 2024 | -97,770.00 |
| Sep 30, 2024 | -670,599.00 |
| Sep 30, 2024 | -670,599.00 |
| Jun 30, 2024 | -542,208.00 |
| Jun 30, 2024 | -542,208.00 |
| Mar 31, 2024 | -668,736.00 |
| Mar 31, 2024 | -668,736.00 |